ABX Review Sample Clauses

ABX Review. Within [*] days of receiving an Evaluation Notice from GNE, ABX shall notify GNE as to whether any of the conditions set forth under Section 3.1.2 (i)-(iii) below (each such condition, an "Impediment") exist with respect to each Specified Antigen which is the subject of such Evaluation Notice, and if so, ABX shall provide to GNE a reasonable description of such Impediment, subject to any confidentiality restrictions to which ABX may be a party. If ABX notifies GNE that an Impediment exists with respect to the Specified Antigen that is the subject of the Evaluation Notice, GNE shall not have the right to obtain an Evaluation Position for such Specified Antigen, provided, however, that if ABX has Selected a Specified Antigen for its own account under Section 3.1.2(i) below, ABX agrees to discuss with GNE the possibility of entering into a collaboration with respect to such Specified Antigen. Impediments are as follows: -------------- * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 7
Sample 1
AutoNDA by SimpleDocs
ABX Review. (a) Within thirty (30) days of receiving an Option Notice from JTI (the "Review Period"), ABX shall notify JTI in writing as to whether any of the conditions set forth in this Section 3.2.2 (each such condition, an "Impediment") exist as of the date upon which ABX receives the Option Notice with respect to each Permitted Antigen which is the subject of such Option Notice, and shall represent the same in such notice. In such event, ABX shall provide to JTI a reasonable description of such Antigen, such Impediment and the date upon which such Impediment arose; PROVIDED THAT in the event that ABX reasonably believes that such a disclosure may cause ABX to breach a confidentiality obligation, the Parties shall discuss in good faith a reasonable resolution to such situation. If ABX notifies JTI that an Impediment exists with respect to the Permitted Antigen that is the subject of the Option Notice, JTI shall not have the right to obtain an Option for such Permitted Antigen. Impediments are as follows:
Sample 1

Related to ABX Review

  • Independent Review Each of the parties hereto has reviewed this Release with its own counsel and advisors.

  • Periodic Review The Compensation Committee or the Board of Directors of the Company shall review Executive's Base Salary and Benefits (as defined below) from time to time in accordance with the normal business practices of the Company. The Company may in its sole discretion increase the Base Salary during the Term. The amount of any increase combined with the previous year's Base Salary shall then constitute Executive's Base Salary for purposes of this Agreement.

  • Periodic Reviews During January of each year during the term hereof, the Board of Directors of the Company shall review Executive's Annual Salary, bonus, stock options, and additional benefits then being provided to Executive. Following each such review, the Company may in its discretion increase the Annual Salary, bonus, stock options, and benefits; however, the Company shall not decrease such items during the period Executive serves as an employee of the Company. Prior to November 30th of each year during the term hereof, the Board of Directors of the Company shall communicate in writing the results of such review to Executive.

  • Contract Review Agent shall have reviewed all material contracts of Borrowers including, without limitation, leases, union contracts, labor contracts, vendor supply contracts, license agreements and distributorship agreements and such contracts and agreements shall be satisfactory in all respects to Agent;

  • Review The AML Compliance Officer shall be responsible for reviewing, no less frequently than annually, the AML training described herein. AUDIT

  • Quarterly Review For a period commencing on the initial effective date of the Registration Statement and ending five years from the date of the consummation of the Business Combination or until such earlier time at which the Liquidation occurs or the Common Stock and Warrants cease to be publicly traded, the Company, at its expense, shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial statements for each of the first three fiscal quarters prior to the announcement of quarterly financial information, the filing of the Company’s Form 10-Q quarterly report and the mailing, if any, of quarterly financial information to stockholders.

  • Performance Review The Company will periodically review Executive’s performance on no less than an annual basis and will make adjustments to salary or other compensation, as they deem appropriate in their sole and absolute discretion.

  • Compensation Review The compensation of the Executive will be reviewed not less frequently than annually by the board of directors of the Company.

  • Document Review The Company and the Executive hereby acknowledge and agree that each (i) has read this Agreement in its entirety prior to executing it, (ii) understands the provisions and effects of this Agreement, (iii) has consulted with such attorneys, accountants and financial and other advisors as it or he has deemed appropriate in connection with their respective execution of this Agreement, and (iv) has executed this Agreement voluntarily and knowingly.

  • Performance Reviews Performance reviews will be conducted at least annually by the President/CEO or designee.

Time is Money Join Law Insider Premium to draft better contracts faster.